Skip to main content

Table 1 Type of systemic therapies employed as the immediate subsequent therapeutic line after TREnd (physician choice), classified by pharmacological classes

From: Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial

 

Number

Subsequent chemotherapy (n = 69, 66%)

 Capecitabine-containing (n = 30)

Capecitabine

22

Capecitabine + vinorelbine

6

Capecitabine + vinorelbine + cyclophosphamide

2

 Taxane-based (n = 21)

Paclitaxel

20

Paclitaxel + BYL79*

1

 Anthracycline-based (n = 9)

Doxorubicin

1

Epirubicin

1

Doxorubicin + cyclophosphamide

7

 Platinum-containing (n = 2)

Cisplatin

1

Cisplatin + cyclophosphamide

1

 Others (n = 7)

Vinorelbine

3

Cyclophosphamide + methotrexate

2

Cyclophosphamide + vinorelbine

2

Subsequent endocrine therapy (n = 33, 31%)

 Fulvestrant (n = 20)

 

20

 AIs (n = 7)

Letrozole

2

Anastrozole

1

Exemestane

4

 AI + mTORi (n = 6)

Exemestane + everolimus

5

Exemestane + everolimus + BYL719*

1

Subsequent other targeted/novel therapies (n = 3, 3%)

 Lucitanib

1

 Ribociclib (single agent)

1

 64-Cu-asparagine

1

  1. AIs aromatase inhibitors, mTORi inhibitors of mammalian target of rapamycin
  2. *BYL719 = alpelisib (PI3K inhibitor)